Jennison Associates’s Praxis Precision Medicines PRAX Stock Holding History

Jennison Associates’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,922	Closed	-$3.82M	–	687
2021 Q4	$3.82M	Sell	12,922 -106	-0.8%	-$31.1K	﹤0.01%	484
2021 Q3	$3.61M	Sell	13,028 -139	-1%	-$37.7K	﹤0.01%	505
2021 Q2	$3.61M	Hold	13,167	–	–	﹤0.01%	521
2021 Q1	$6.47M	Sell	13,167 -111	-0.8%	-$78.9K	﹤0.01%	455
2020 Q4	$11M	Buy	+13,278	New	+$7.75M	0.01%	396

Other funds holding PRAX

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jennison Associates's PRAX Position: Q1 2022 in Review

Jennison Associates sold out of Praxis Precision Medicines (PRAX) in Q1 2022, closing a stake of 12,922 shares — an estimated $3.82M sold.

Jennison Associates first reported a position in PRAX in Q4 2020 and held it in 5 quarters. The position peaked at $11M in Q4 2020. 103 funds tracked by Wall St. Rank hold PRAX as of Q1 2022.

Jennison Associates reported no remaining Praxis Precision Medicines position as of Q1 2022 after selling out during the quarter.
Jennison Associates sold 12,922 Praxis Precision Medicines shares in Q1 2022, an estimated $3.82M.
Jennison Associates first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 5 quarters.
Jennison Associates's Praxis Precision Medicines position peaked at $11M in Q4 2020.
103 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.